☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
unresectable hepatocellular carcinoma
Roche's Tecentriq in Combination with Avastin Receives China NMPA's Approval for the Treatment of Unresectable Hepatocellular Carc...
October 30, 2020
Chugai's Tecentriq (atezolizumab) and Avastin (bevacizumab) Receive MHLW's Approval as 1L Treatment for Unresectable Hepatocellula...
September 28, 2020
Roche Reports Results of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 for Unresectable Hepatocellular Carc...
November 25, 2019
Roche Reports Result of Tecentriq (atezolizumab) + Avastin (bevacizumab) in P-III IMbrave150 Study for Unresectable Hepatocellular...
October 21, 2019
Eisai and Merck Annouces the US FDA Approval of Lenvima for Unresectable 1L Hepatocellular Carcinoma (HCC)
August 17, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.